Effect of Pralsetinib on lung adenocarcinoma

RET rearrangements are rare, occurring in 1%-2% of all patients with non-small cell lung cancer (NSCLC). Pralsetinib has significant anti-tumor effects in patients with advanced non-small cell lung cancer and RET rearrangement, and previous studies have confirmed the effectiveness of neoadjuvant targeted therapy in non-small cell lung cancer.

A clinical trial calledARROW found that platinib showed encouraging therapeutic effects in the treatment of patients with advanced or metastatic RET-mutated non-small cell lung cancer. The study showed that platinib led to tumor shrinkage of up to 57% in these patients. In addition, platinib can also extend the progression-free survival of patients. According to the results of clinical trials, platinib has shown significant efficacy in the treatment of lung adenocarcinoma patients with RET gene mutations. But every patient's response and condition is different, so the specific effects of using platinib may vary from person to person.

It is understood that the original drug Platinib has been launched in China, but it has not yet entered the scope of medical insurance. The price of each box of 100mg*120 tablets may be around 60,000 yuan, which is expensive. The price of the European version of 100mg*60 capsules sold overseas may be around 40,000 yuan per box, and the price of the American version may be around 150,000 yuan per box (prices may fluctuate due to exchange rates). The ingredients of domestic and foreign original drugs are basically the same. There is currently no generic version of Platinib available on the market. Please consult your medical consultant for specific prices and drug details.